Browse > Article

Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer  

Bae, Kang Woo (Department of Internal Medicine, Dankook University College of Medicine)
Song, Tak Ho (Department of Internal Medicine, Dankook University College of Medicine)
Yang, Joo Yeon (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Yun Seup (Department of Internal Medicine, Dankook University College of Medicine)
Park, Jae Seok (Department of Internal Medicine, Dankook University College of Medicine)
Jee, Young Koo (Department of Internal Medicine, Dankook University College of Medicine)
Lee, Kye Young (Department of Internal Medicine, Dankook University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.4, 2004 , pp. 351-357 More about this Journal
Abstract
Background : Paclitaxel is highly beneficial anticancer drug for the treatment of non-small cell lung cancer and has shown remarkable radiosensitizing effect in vitro. We evaluated whether concurrent chemoradiation therapy with weekly paclitaxel (60 $mg/m^2$) could be tolerated and effective in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods : Twenty-two stage III (IIIA:6, IIIB:16) NSCLC patients were treated with weekly administration of paclitaxel (60 $mg/m^2$) on days 1, 8, 15, 22, 29, and 36 in addition to concurrent radiation therapy of 54 Gy. After the initial phase of concurrent chemoradiation, patients received additional two cycles of consolidation chemotherapy with paclitaxel (175 $mg/m^2$)/cisplatin (75 $mg/m^2$) or paclitaxel (175 $mg/m^2$)/carboplatin (6AUC) every 3 weeks. Results : Overall response rate was 81.8% (18/22) with 9.1% (2/22) of complete response and 72.7% (16/22) of partial response rate. Two patients (9.1%) died of chemoradiation-induced pneumonitis after completion of therapy. In total, grade 3 toxicities included pneumonitis (22.7%), esophagitis (22.7%), neuropathy (13.6%), and neutropenia (13.6%). The median survival time was 15 months and 2-year overall survival were 31.8%. Conclusion : Concurrent chemoradiation therapy with weekly paclitaxel in locally advanced NSCLC showed good local response, but survival rate was not completely satisfactory due to potentially fatal chemoradiation-induced pneumonitis.
Keywords
NSCLC; Concurrent chemoradiation; Weekly paclitaxel;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Petrovich Z, Stanley K, Cox JD, Paig C. Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer 1981;48:1335-40
2 Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9
3 Curran WJ, Scott C, Langer C. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unrescted stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;10:1891
4 Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel.Cancer Res 1995;55:3564-8
5 Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable nonsmallcell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-64
6 Jassem J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Lancet Oncol 2001;2:335–42
7 Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, et al. Significant effect of adjuvant chemotherapy on survival in locallyadvanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58
8 Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5
9 Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern CooperativeOncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205
10 Johnson DH. Locally advanced, unresectable nonsmall cell lung cancer: new treatment strategies. Chest 2000; 117(4 Suppl 1):123S-126S
11 Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res1994;54:3506-10
12 Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel orvinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-8
13 Cox JD, Pajak TF, Herskovic A, Urtasun R, Podolsky WJ, Seydel HG. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08. Am J Clin Oncol 1991;14:280-4
14 Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III nonsmall-cell lung cancer: seven-year follow-up of cancer and leukemia group B [CALGB] 8433 trial. J Natl Cancer Inst 1996; 88:1210–5
15 Belani CP. Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations. Chest 2000; 117 (4 Suppl 1):127S-132S
16 Gaspar LE. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cnacer. Curr Opin Oncol 2001;13:110-5
17 Kirkbride P, Gelmon K, Eisenhauer E. Pacltaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin Radiat Oncol 1999;9:102-7
18 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47: 207-14
19 Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advancednon-small cell lung cancer. J Clin Oncol 1994;12:2682-6
20 Rowisky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14
21 Caffo O. Radiosensitization with chemotherapeutic agents. Lung Cancer 2001;34 (Suppl 4):S81-90
22 Jassem J. Combined modality treatment with chemotherapy and radiation in locally advanced non-small cell lung cancer. Lung Cancer 2001;34(Suppl 2):S181-3
23 Movsas B, Scott C, Curran WJ. A quality-adjusted time without symptoms or toxicity (QTWIST). Analysis of Radiation Therapy Oncology Group [RTOG] 9410. Proc Am Soc Clin Oncol 2001;20:313a.(Abstract)
24 Zanelli GD, Quaia M, Robieux I, Bujor L, Santarosa M, Favaro D, et al. Paclitaxel as a radiosensitizer: a proposed schedule of administration based on in vitrodata and pharmacokinetic calculations. Eur J Cancer 1997;33:486-92
25 Greco FA. Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2001;34(Suppl 4):S53-6